The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis
Open accessAbstract
The ANCA associated vasculitides (AAV) comprise are a group of conditions characterized by inflammation and necrosis of small and medium-sized blood vessels. They comprise Wegener's granulomatosis, Churg–Strauss syndrome and microscopic polyangiitis. Early diagnosis and treatment is important as the presence of advanced disease at diagnosis limits the potential benefit of therapy. The aim of this document is to provide guidelines for the management of adults with systemic vasculitis. The guidelines concentrate on the indications for using cyclophosphamide and the different therapeutic regimens available. The guideline does not cover the treatment of children or other types of systemic vasculitis. The target audience is rheumatologists, nephrologists and general physicians, together with trainees and nurse practitioners. This is a short summary of the whole guideline. The full guideline is available on the journal website. We have produced evidence-based recommendations for treatment giving a grade of recommendation (from A to C) and an algorithm to illustrate the approach to the management of a patient with newly diagnosed AAV. Eligibility for treatment and use of this guideline depends on the assumption that a definite diagnosis of vasculitis has been made. The following criteria must be fulfilled prior to a diagnosis of vasculitis: Symptoms and signs characteristic of systemic vasculitis. At least one of the following: Histological evidence of vasculitis and/or granuloma formation, Positive serology for ANCA (either cANCA/PR3 or pANCA/MPO), Specific indirect evidence of vasculitis. No other diagnosis to account for symptoms or signs. It is important to consider other causes of systemic illness, especially malignancy, infection (particularly bacterial endocarditis) and drugs. Treatment for vasculitis requires induction of remission followed by maintenance (A). Current treatment is based on assessing the severity and extent of disease and subdividing the disease into three groups: (i) localized and/or early, (ii) generalized disease with threatened organ involvement and (iii) severe/life threatening disease (C). Algorithm of guideline. Localized/early systemic disease Treatment should be with either cyclophosphamide or methotrexate. Methotrexate may be associated with a higher relapse rate (A). Evidence of progression or relapse should be treated with cyclophosphamide (B). Localized disease can cause significant local destruction and requires treatment with cyclophosphamide treatment (C). Generalized/threatened organ involvement Initial treatment of generalized/organ threatening disease should include cyclophosphamide and steroids (A). Cyclophosphamide may be given as continuous low dose oral treatment or by intravenous pulses initially at 2-week intervals and then 3 weekly (A). There is no difference in remission rates and no increased risk of relapse between IV and oral regimens (A). Continuous low dose oral cyclophosphamide was associated with a higher total cyclophosphamide dosage and a significant increase in infection risk. Transfer to maintenance therapy at 3 months when receiving continuous low dose oral cyclophosphamide and at 3–6 months when receiving pulsed intravenous cyclophosphamide if successful disease remission has been achieved (A). In both cases, the aim should be for a maximum duration of therapy of 6 months where successful disease remission has been achieved. Severe/life threatening disease Patients with AAV presenting with severe renal failure (creatinine >500 μmol/l) should be treated with cyclophosphamide (either pulsed IV or continuous low dose oral) and steroids, with adjuvant plasma exchange (A). Plasma exchange should also be considered in those with other life threatening manifestations of disease such as pulmonary haemorrhage (C). Steroids Steroids are usually given as daily oral prednisolone. Initially at relatively high doses; 1 mg/kg up to 60 mg (A). Intravenous steroids (250–500 mg methylpredinisolone) are sometimes given just prior to/with the first two pulses of cyclophosphamide (A). Patients intolerant of cyclophosphamide For cases where patients are intolerant of cyclophosphamide, alternative treatments such as methotrexate, azathioprine, leflunomide or mycophenolate mofetil may be used (B,C). Maintenance therapy Following achievement of successful remission, cyclophosphamide should be withdrawn and substituted with either azathioprine or methotrexate (A). Mycophenolate or leflunomide may be used as alternatives for intolerance or lack of efficacy of azathioprine or methotrexate (C). Patients should continue maintenance therapy for at least 24 months following successful disease remission (B). Patients with Wegener's granulomatosis or patients who remain ANCA positive should continue immunosuppression for up to 5 years (C). Relapsing disease Minor relapse is treated with an increase in prednisolone dosage and optimization of concurrent immunosuppression (C). Major rela
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
The american college of rheumatology 1990 criteria for the classification of fibromyalgia
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330203 · Cited by 9,563
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationThe MOS Short-form General Health Survey: Reliability and Validity in a Patient Population
Stewart, A. L., Hays, R. D., & Ware, J. E. (1988) · Medical Care · doi:10.1097/00005650-198807000-00007 · Cited by 3,339
Masi, A. T., Hunder, G. G., Lie, J. T., Michel, B. A., Bloch, D. A., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330806 · Cited by 2,215
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Leavitt, R. Y., Fauci, A. S., Bloch, D. A., Michel, B. A., Hunder, G. G., Arend, W. P., Calabrese, L. H., Fries, J. F., Lie, J. T., Lightfoot, R. W., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330807 · Cited by 1,947
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
Self-citationSystemic Vasculitis with Asthma and Eosinophilia: A Clinical Approach to the Churg-Strauss Syndrome
LANHAM, J. G., ELKON, K. B., PUSEY, C. D., & HUGHES, G. R. (1984) · Medicine · doi:10.1097/00005792-198403000-00001 · Cited by 1,238
Jayne, D. R. W., Gaskin, G., Rasmussen, N., Abramowicz, D., Ferrario, F., Guillevin, L., Mirapeix, E., Savage, C. O. S., Sinico, R. A., Stegeman, C. A., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010090 · Cited by 1,125
Self-citation
Cited by
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
Self-citationEULAR recommendations for the management of primary small and medium vessel vasculitis
Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C. G. M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088096 · Cited by 990
Self-citationPathogenesis and therapeutic interventions for ANCA-associated vasculitis
Nakazawa, D., Masuda, S., Tomaru, U., & Ishizu, A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0145-y · Cited by 477
Tasaka, S., & Tokuda, H. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0453-0 · Cited by 123
Metadata
- Authors
- Lapraik, C., Watts, R., Bacon, P., Carruthers, D., Chakravarty, K., D’Cruz, D., Guillevin, L., Harper, L., Jayne, D., Luqmani, R., Mooney, J., & Scott, D.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-09-05
- Volume
- 46
- Issue
- 10
- Pages
- 1615-1616
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2131153587
- Cited by
- 369
- References
- 59
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. https://app.cochat.ai/papers/10.1093/rheumatology/kem146a
- The paper
- Lapraik, C., Watts, R., Bacon, P., Carruthers, D., Chakravarty, K., D’Cruz, D., Guillevin, L., Harper, L., Jayne, D., Luqmani, R., Mooney, J., & Scott, D. (2007). BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. https://doi.org/10.1093/rheumatology/kem146a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.